Table 2 All-grade AEs (occurring in ≥20 %) or grade 3–4 AEsa (occurring in >3 %) in phase 2a
Adverse event, n (%) | Grades 1 and 2 | Grade 3 | Grade 4 | ||||
|---|---|---|---|---|---|---|---|
Group A (n = 22) | Group B (n = 22) | Group A (n = 22) | Group B (n = 22) | Group A (n = 22) | Group B (n = 22) | Total (N = 44) | |
Peripheral neuropathy | 18 (81.8) | 14 (63.6) | 2 (9.1) | 6 (27.3) | – | – | 40 (90.9) |
Fatigue | 13 (59.1) | 16 (72.7) | 3 (13.6) | 3 (13.6) | – | – | 35 (79.5) |
Nausea | 9 (40.9) | 9 (40.9) | 1 (4.5) | 1 (4.5) | – | – | 20 (45.5) |
Dry eye | 6 (27.3) | 11 (50.0) | – | 1 (4.5) | – | – | 18 (40.9) |
Alopecia | 6 (27.3) | 11 (50.0) | – | – | – | – | 17 (38.6) |
Arthralgia | 9 (40.9) | 7 (31.8) | – | – | – | – | 16 (36.4) |
Epistaxis | 5 (22.7) | 11 (50.0) | – | – | – | – | 16 (36.4) |
Diarrhea | 4 (18.2) | 10 (45.5) | – | 1 (4.5) | – | – | 15 (34.1) |
Thrombocytopenia | 3 (13.6) | 3 (13.6) | 3 (14.6) | 2 (9.1) | 2 (9.1) | – | 13 (29.5) |
Decreased appetite | 5 (22.7) | 7 (31.8) | – | – | – | – | 12 (27.3) |
Neutropenia | 1 (4.5) | – | 5 (22.7) | 3 (13.6) | 2 (9.1) | 1 (4.5) | 12 (27.3) |
Rash | 2 (9.1) | 9 (40.9) | 1 (4.5) | – | – | – | 12 (27.3) |
Vision blurred | 6 (27.3) | 6 (27.3) | – | – | – | – | 12 (27.3) |
Myalgia | 4 (18.2) | 6 (27.3) | 1 (4.5) | – | – | – | 11 (25.0) |
Dyspnea | 3 (13.6) | 7 (31.8) | – | – | – | – | 10 (22.7) |
Anemia | 2 (9.1) | 4 (18.2) | 2 (9.1) | 1 (4.5) | – | – | 9 (20.5) |
Constipation | 4 (18.2) | 4 (18.2) | 1 (4.5) | – | – | – | 9 (20.5) |
Cough | 4 (18.2) | 5 (22.7) | – | – | – | – | 9 (20.5) |
Mucosal inflammation | 1 (4.5) | 4(18.2) | 1 (4.5) | 1 (4.5) | – | – | 7 (15.9) |
Muscular weakness | 1 (4.5) | – | – | 2 (9.1) | – | – | 3 (6.8) |
Decreased hemoglobin | – | – | – | 1 (4.5) | 1 (4.5) | – | 2 (4.5) |